Evidence map›Paper›PMID 35185519›Full record

ArticleFrontiers in aging neuroscience2021

Identification of Multicolor Fluorescent Probes for Heterogeneous Aβ Deposits in Alzheimer's Disease.

Abhisek Mukherjee, Rabab Al-Lahham, Mark E Corkins, Sourav Samanta, Ann M Schmeichel, Wolfgang Singer, Phillip A Low, Thimmaiah Govindaraju, Claudio Soto

Open access · goldAbstract read
In one paragraph

Article in Frontiers in aging neuroscience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Abhisek MukherjeeDepartment of Neurology, Mitchell Center for Alzheimer's Disease and Related Brain Disorders, McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, United States.
Rabab Al-LahhamDepartment of Neurology, Mitchell Center for Alzheimer's Disease and Related Brain Disorders, McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, United States.
Mark E CorkinsDepartment of Pediatrics, McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, United States.
Sourav SamantaBioorganic Chemistry Laboratory, New Chemistry Unit, Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR), Bengaluru, India.
Ann M SchmeichelDepartment of Neurology, Mayo Clinic, Rochester, MN, United States.
Wolfgang SingerDepartment of Neurology, Mayo Clinic, Rochester, MN, United States.
Phillip A LowDepartment of Neurology, Mayo Clinic, Rochester, MN, United States.
Thimmaiah GovindarajuBioorganic Chemistry Laboratory, New Chemistry Unit, Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR), Bengaluru, India.
Claudio SotoDepartment of Neurology, Mitchell Center for Alzheimer's Disease and Related Brain Disorders, McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, United States.
The University of Texas Health Science Center at Houston · USMayo Clinic in Arizona · USJawaharlal Nehru Centre for Advanced Scientific Research · IN

Funding

Role of circulating Abeta seeds and peripheral tissue damage in Alzheimer's disease pathogenesisRF1AG059321 · NIA · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MORALES, RODRIGO, SOTO, CLAUDIO · 2020 to 2020
$2.9M
Novel Role of Nephron Epithelialization in Nuclear SignalingR01DK115655 · NIDDK · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Rachel Katherine Miller · 2019 to 2026
$2.3M
Infection-driven mechanisms associated with Alzheimer's disease pathologyRF1AG072491 · NIA · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI BARICHELLO, TATIANA, MORALES, RODRIGO · 2021 to 2021
$2.0M
Role of circulating Abeta seeds and peripheral tissue damage in Alzheimer's disease pathogenesisR01AG059321 · NIA · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MORALES, RODRIGO, SOTO, CLAUDIO · 2024 to 2024
$718k
Role of p53 in Kidney Development: Modeling Renal Anomalies of Li-Fraumeni PatientsR03DK118771 · NIDDK · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MILLER, RACHEL KATHERINE · 2018 to 2019
$231k
NIA NIH HHS R01 AG059321NIA NIH HHS RF1 AG059321NIA NIH HHS RF1 AG072491NIDDK NIH HHS R01 DK115655NIDDK NIH HHS R03 DK118771
6 · The paper itself

Abstract

Accumulation of amyloid-beta (Aβ) into amyloid plaques and hyperphosphorylated tau into neurofibrillary tangles (NFTs) are pathological hallmarks of Alzheimer's disease (AD). There is a significant intra- and inter-individual variability in the morphology and conformation of Aβ aggregates, which may account in part for the extensive clinical and pathophysiological heterogeneity observed in AD. In this study, we sought to identify an array of fluorescent dyes to specifically probe Aβ aggregates, in an effort to address their diversity. We screened a small library of fluorescent probes and identified three benzothiazole-coumarin derivatives that stained both vascular and parenchymal Aβ deposits in AD brain sections. The set of these three dyes allowed the visualization of Aβ deposits in three different colors (blue, green and far-red). Importantly, two of these dyes specifically stained Aβ deposits with no apparent staining of hyperphosphorylated tau or α-synuclein deposits. Furthermore, this set of dyes demonstrated differential interactions with distinct types of Aβ deposits present in the same subject. Aβ aggregate-specific dyes identified in this study have the potential to be further developed into Aβ imaging probes for the diagnosis of AD. In addition, the far-red dye we identified in this study may serve as an imaging probe for small animal imaging of Aβ pathology. Finally, these dyes in combination may help us advance our understanding of the relation between the various Aβ deposits and the clinical diversity observed in AD.

Indexed as

Alzheimer’s diseaseamyloid plaque heterogeneityAβ plaquesfluorescent probesLewy bodiesneuritic plaquesneurofibrillary tangles

Identifiers

PMID35185519
PMCPMC8852231
OpenAlexW4210269724

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.